Brokerages expect Alkermes Plc (NASDAQ:ALKS) to report sales of $221.82 million for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Alkermes’ earnings. The highest sales estimate is $228.70 million and the lowest is $214.94 million. Alkermes reported sales of $191.78 million in the same quarter last year, which would suggest a positive year over year growth rate of 15.7%. The business is expected to report its next quarterly earnings report on Thursday, April 26th.

On average, analysts expect that Alkermes will report full-year sales of $1.00 billion for the current fiscal year, with estimates ranging from $987.90 million to $1.02 billion. For the next year, analysts anticipate that the company will report sales of $1.10 billion per share, with estimates ranging from $940.10 million to $1.21 billion. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that follow Alkermes.

How to Become a New Pot Stock Millionaire

Alkermes (NASDAQ:ALKS) last issued its earnings results on Wednesday, February 14th. The company reported $0.31 earnings per share for the quarter, topping the consensus estimate of ($0.01) by $0.32. Alkermes had a negative return on equity of 4.32% and a negative net margin of 17.48%. The business had revenue of $275.37 million for the quarter, compared to analyst estimates of $251.23 million. During the same period last year, the company posted $0.02 EPS. The business’s quarterly revenue was up 29.0% on a year-over-year basis.

Several analysts recently issued reports on ALKS shares. Zacks Investment Research upgraded Alkermes from a “hold” rating to a “buy” rating and set a $61.00 price target for the company in a report on Monday, January 8th. Credit Suisse Group set a $66.00 price target on Alkermes and gave the company a “buy” rating in a report on Wednesday, February 14th. BidaskClub upgraded Alkermes from a “hold” rating to a “buy” rating in a report on Wednesday, March 28th. JPMorgan Chase set a $63.00 price target on Alkermes and gave the company a “buy” rating in a report on Tuesday, April 3rd. Finally, Morgan Stanley reiterated an “equal weight” rating and issued a $67.00 price target (up from $60.00) on shares of Alkermes in a report on Friday, February 23rd. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and five have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $61.50.

Shares of NASDAQ ALKS opened at $44.43 on Tuesday. Alkermes has a 12-month low of $41.15 and a 12-month high of $71.22. The firm has a market capitalization of $6,592.20, a P/E ratio of -120.08 and a beta of 1.81. The company has a debt-to-equity ratio of 0.23, a current ratio of 2.78 and a quick ratio of 2.46.

In other news, Director Paul J. Mitchell sold 1,000 shares of the firm’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $56.77, for a total transaction of $56,770.00. Following the completion of the sale, the director now directly owns 9,000 shares in the company, valued at $510,930. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Shane Cooke sold 1,700 shares of the firm’s stock in a transaction dated Friday, January 26th. The shares were sold at an average price of $60.02, for a total value of $102,034.00. Following the sale, the insider now owns 76,408 shares of the company’s stock, valued at $4,586,008.16. The disclosure for this sale can be found here. Insiders have sold 91,673 shares of company stock valued at $5,635,250 over the last 90 days. Insiders own 5.34% of the company’s stock.

Several institutional investors have recently made changes to their positions in the company. Woodford Investment Management Ltd grew its stake in shares of Alkermes by 3.4% during the fourth quarter. Woodford Investment Management Ltd now owns 7,585,683 shares of the company’s stock valued at $310,628,000 after acquiring an additional 250,000 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Alkermes by 18.3% during the fourth quarter. Goldman Sachs Group Inc. now owns 4,054,645 shares of the company’s stock valued at $221,911,000 after acquiring an additional 628,299 shares in the last quarter. Geode Capital Management LLC grew its stake in Alkermes by 1.6% in the fourth quarter. Geode Capital Management LLC now owns 1,333,429 shares of the company’s stock worth $72,934,000 after purchasing an additional 21,608 shares in the last quarter. First Trust Advisors LP grew its stake in Alkermes by 18.6% in the fourth quarter. First Trust Advisors LP now owns 800,752 shares of the company’s stock worth $43,825,000 after purchasing an additional 125,309 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. grew its stake in Alkermes by 5.0% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 493,515 shares of the company’s stock worth $27,011,000 after purchasing an additional 23,712 shares in the last quarter.

COPYRIGHT VIOLATION NOTICE: “Alkermes Plc (ALKS) Expected to Post Quarterly Sales of $221.82 Million” was first posted by Daily Political and is owned by of Daily Political. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://www.dailypolitical.com/2018/04/17/alkermes-plc-alks-expected-to-post-quarterly-sales-of-221-82-million.html.

Alkermes Company Profile

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Get a free copy of the Zacks research report on Alkermes (ALKS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Alkermes (NASDAQ:ALKS)

Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.